Who
David A. Santos
EVP, Chief Commercial Officer
Company insider
Files Form 4 as: EVP, Chief Commercial Officer, Rigel Pharmaceuticals.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $109K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Aug 2020
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $42K874 at $47.50 | filing |
| 1 Sep 2026filed 3 Sep 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $42K874 at $47.50 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $26K874 at $29.86 | filing |
| 1 Jun 2026filed 3 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $26K874 at $29.86 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —19,430 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —19,430 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $123K3,546 at $34.62 | filing |
| 10 Feb 2026filed 12 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $123K3,546 at $34.62 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $206K5,718 at $36.01 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $206K5,718 at $36.01 | filing |
| 15 Sep 2025filed 17 Sep 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,394 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,875 at $0.00 | filing |
| 17 Mar 2025filed 19 Mar 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,850 at $0.00 | filing |
| 5 Feb 2025filed 6 Feb 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $39K1,796 at $21.93 | filing |
| 4 Feb 2025filed 6 Feb 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $44K2,125 at $20.92 | filing |
| 29 Jan 2025filed 31 Jan 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,788 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —19,717 at $0.00 | filing |
| 25 Nov 2024filed 26 Nov 2024 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.